Fundies. English
Segment disclosures
Company overviewEndo, Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
30 dimension combinations 210 retained observations 10 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Adrenalin · Sterile Injectables Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:AdrenalinMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:SterileInjectablesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 14051000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 60207000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 21463000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 36105000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 14642000 | USD | 20240829 | Open filing evidence |
Established Products · Branded Pharmaceuticals Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:EstablishedProductsMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 49162000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 151771000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 57747000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 92987000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 35240000 | USD | 20240829 | Open filing evidence |
Other Established Products · Branded Pharmaceuticals Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:OtherEstablishedProductsMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 16886000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 60413000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 24999000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 37947000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 12948000 | USD | 20240829 | Open filing evidence |
Other Specialty Products · Branded Pharmaceuticals Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:OtherSpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 11583000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 36147000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 12311000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 21651000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 9339000 | USD | 20240829 | Open filing evidence |
Other Sterile Injectables · Sterile Injectables Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:OtherSterileInjectablesMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:SterileInjectablesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 48934000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 132307000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 43253000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 77159000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 33906000 | USD | 20240829 | Open filing evidence |
PERCOCET · Branded Pharmaceuticals Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:PERCOCETMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 21986000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 63486000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 24144000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 38054000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 13910000 | USD | 20240829 | Open filing evidence |
Specialty Products · Branded Pharmaceuticals Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:SpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 160329000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 458439000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 159433000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 270345000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 110911000 | USD | 20240829 | Open filing evidence |
SUPPRELINLA · Branded Pharmaceuticals Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:SUPPRELINLAMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 27380000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 59307000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 19130000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 33648000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 14518000 | USD | 20240829 | Open filing evidence |
Testopel · Branded Pharmaceuticals Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:TestopelMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 10290000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 27872000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 8604000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 16986000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 8382000 | USD | 20240829 | Open filing evidence |
Vasostrict · Sterile Injectables Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:VasostrictMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:SterileInjectablesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 8286000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 36354000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 15412000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 23338000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 7926000 | USD | 20240829 | Open filing evidence |
Xiaflex · Branded Pharmaceuticals Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=ndoi:XiaflexMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 121366000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 362985000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 127992000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 215046000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 87054000 | USD | 20240829 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Adrenalin · Sterile Injectables Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:AdrenalinMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:SterileInjectablesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 11233000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 38601000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 27367000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 99910000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 22873000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 75581000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 27133000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 52708000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 114304000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Established Products · Branded Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:EstablishedProductsMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 27350000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 79743000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 52393000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 213427000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 52976000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 155392000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 47024000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 102416000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 229442000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Other Established Products · Branded Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:OtherEstablishedProductsMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 15268000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 32626000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 17358000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 64588000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 17076000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 44402000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 8979000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 27326000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 86772000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Other Specialty Products · Branded Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:OtherSpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 5902000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 21120000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 15219000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 73797000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 15749000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 57282000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 19839000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 41533000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 70009000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Other Sterile Injectables · Sterile Injectables Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:OtherSterileInjectablesMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:SterileInjectablesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 15708000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 59621000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 43914000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 236473000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 51681000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 186886000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 85476000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 135205000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 221633000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · PERCOCET · Branded Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:PERCOCETMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 9348000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 33892000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 24544000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 106375000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 26290000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 78791000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 26445000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 52501000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 103943000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Specialty Products · Branded Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:SpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 51568000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 199971000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 148403000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 645660000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 150392000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 457926000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 165353000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 307534000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 621700000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · SUPPRELINLA · Branded Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:SUPPRELINLAMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 6078000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 26213000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 20135000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 96849000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 21590000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 73390000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 28223000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 51800000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 113011000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Testopel · Branded Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:TestopelMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 2734000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 13225000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 10491000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 42464000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 9610000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 32199000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 11600000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 22589000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 38727000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Vasostrict · Sterile Injectables Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:VasostrictMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:SterileInjectablesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 7356000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 34309000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 26953000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 93180000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 20827000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 71197000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 24419000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 50370000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 253696000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Xiaflex · Branded Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Product Or Service · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;srt:ProductOrServiceAxis=ndoi:XiaflexMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 39588000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 152638000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 113049000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 475014000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 113053000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 327254000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 117291000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 214201000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 438680000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Branded Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 78918000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 279714000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 200796000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 859087000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 203368000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 613318000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 212377000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 409950000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 851142000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Generic Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:GenericPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 40360000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 143677000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 103317000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 650352000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 134382000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 511141000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 178579000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 376759000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 795457000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · International Pharmaceuticals Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:InternationalPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 8892000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 26052000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 17160000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 72516000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 18534000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 55661000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 18868000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 37127000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 82643000 | USD | 20250313 | Open filing evidence |
Reorganization Chapter11 Predecessor Before Adjustment · Sterile Injectables Segment
Fresh Start Adjustments Type Of Fresh Start Adjustment · Statement Business Segments
Source dimensions
us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap:ReorganizationChapter11PredecessorBeforeAdjustmentMember;us-gaap:StatementBusinessSegmentsAxis=ndoi:SterileInjectablesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-04-23 | 34297000 | USD | 20240829 | Open filing evidence |
| 2024-01-01 – 2024-04-23 | 132531000 | USD | 20250313 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 98234000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 429563000 | USD | 20250313 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 95381000 | USD | 20241105 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 333664000 | USD | 20241105 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 137028000 | USD | 20240829 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 238283000 | USD | 20240829 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 589633000 | USD | 20250313 | Open filing evidence |
Branded Pharmaceuticals Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=ndoi:BrandedPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 209491000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 610210000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 217180000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 363332000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 146151000 | USD | 20240829 | Open filing evidence |
Generic Pharmaceuticals Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=ndoi:GenericPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 99084000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 291430000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 110830000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 180551000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 69722000 | USD | 20240829 | Open filing evidence |
International Pharmaceuticals Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=ndoi:InternationalPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 12987000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 47658000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 18368000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 30184000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 11816000 | USD | 20240829 | Open filing evidence |
Sterile Injectables Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=ndoi:SterileInjectablesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 71271000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 228868000 | USD | 20250313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 80128000 | USD | 20241105 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 136602000 | USD | 20241105 | Open filing evidence |
| 2024-04-24 – 2024-06-30 | 56474000 | USD | 20240829 | Open filing evidence |